A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

NCT00934089 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma, Open-Angle
Ocular Hypertension

Interventions

DRUG: PF-04217329
DRUG: latanoprost vehicle
DRUG: PF-04217329
DRUG: latanoprost

Sponsor

Pfizer